Saputra Gusti Noor Ramadany, Yudhawati Resti, Fitriah Munawaroh
Department of Pulmonology and Respiratory Medicine, Faculty of Medicine, Universitas Airlangga - Dr. Soetomo General Academic Hospital, Surabaya, Indonesia.
Department of Clinical Pathology, Faculty of Medicine, Universitas Airlangga - Dr. Soetomo General Academic Hospital, Surabaya, Indonesia.
Ann Med Surg (Lond). 2022 Feb;74:103303. doi: 10.1016/j.amsu.2022.103303. Epub 2022 Jan 29.
Coronavirus disease 2019 (COVID-19) is a new health problem discovered in 2019 thus requires biomarkers that can detect early tissue damage. Soluble receptor for advanced glycation end-products (sRAGE) is a biomarker that can be used to identify early lung damage.
Analyzing the association of serum sRAGE on COVID-19 severity.
This study employed a cross-sectional design with a consecutive sampling method. It was conducted from May 2020-October 2021. The number of participants in this study was 145 participants which were divided into 2 groups (non-severe = 47 and severe = 98). Association of sRAGE serum on COVID-19 severity was analyzed using the chi-square test, Fisher's exact test, independence -test, Mann Withney test, and Spearman's rank test with -value <0.05.
The results of blood analysis showed several blood components such as leukocytes (9896.51 ± 4949.64/μL; = 2.431; = 0.015), lymphocytes (13.55 ± 8.48%; = 2.256; = 0.024), neutrophils (78.91 ± 10.50%; = 2.464; = 0.014), procalcitonin (0.92 ± 3.22 ng/mL; = 3.323; = 0.001), CRP (8.59 ± 7.62 mg/L; = 2.114; = 0.034), D-dimer (4360.29 ± 7797.81 ng/mL; = 2.186; = 0.029), and fibrinogen (474.58 ± 168.90 mg/dL; = 0.383; = 0.703). There was a significant comparison in serum sRAGE values in the non-severe group (0.78 [0.63-1.00] ng/mL) and severe group (1.47 [0.97-2.25] ng/mL; = 7.154; <0.001). There was a significant association between serum sRAGE and COVID-19 severity ( = 0.598; <0.001). The cut-off value for serum sRAGE between the severe and non-severe groups was 0.985 ng/mL. This study obtained sensitivity of 73.5%, specificity of 74.5% OR 8.077 and AUC 0.868 95% CI.
There is a significant association between serum sRAGE and COVID-19 severity and there is also a significant difference in serum sRAGE in the two groups.
2019冠状病毒病（COVID-19）是2019年发现的一个新的健康问题，因此需要能够检测早期组织损伤的生物标志物。晚期糖基化终产物可溶性受体（sRAGE）是一种可用于识别早期肺损伤的生物标志物。
分析血清sRAGE与COVID-19严重程度的相关性。
本研究采用横断面设计和连续抽样方法。研究于2020年5月至2021年10月进行。本研究的参与者有145人，分为2组（非重症组=47人，重症组=98人）。采用卡方检验、Fisher精确检验、独立性检验、Mann-Whitney检验和Spearman秩检验分析sRAGE血清与COVID-19严重程度的相关性，P值<0.05。
血液分析结果显示了几种血液成分，如白细胞（9896.51±4949.64/μL；t=2.431；P=0.015）、淋巴细胞（13.55±8.48%；t=2.256；P=0.024）、中性粒细胞（78.91±10.50%；t=2.464；P=0.014）、降钙素原（0.92±3.22 ng/mL；t=3.323；P=0.001）、C反应蛋白（8.59±7.62 mg/L；t=2.114；P=0.034）、D-二聚体（4360.29±7797.81 ng/mL；t=2.186；P=0.029）和纤维蛋白原（474.58±168.90 mg/dL；t=0.383；P=0.703）。非重症组血清sRAGE值（0.78[0.63-1.00]ng/mL）与重症组（1.47[0.97-2.25]ng/mL；t=7.154；P<0.001）有显著差异。血清sRAGE与COVID-19严重程度之间存在显著相关性（r=0.598；P<0.001）。重症组与非重症组血清sRAGE的截断值为0.985 ng/mL。本研究获得的灵敏度为73.5%，特异度为74.5%，OR为8.077，AUC为0.868，95%CI。
血清sRAGE与COVID-19严重程度之间存在显著相关性，两组血清sRAGE也存在显著差异。
